首支国产mRNA新冠疫苗接近III期临床,将实现中国mRNA疫苗“零”突破

2021-04-17 “科技导报”公众号 “科技导报”公众号

近日,苏州艾博生物科技有限公司(以下简称“艾博生物”)创始人英博博士接受采访时透露,艾博生物联合军事科学院军事医学研究院、云南沃森生物共同研制的新型冠状病毒mRNA疫苗(ARCoV)已进入II期临床尾

疫情汹涌,风口浪尖上的mRNA疫苗进程一直受到全球密切关注。

近日,苏州艾博生物科技有限公司(以下简称“艾博生物”)创始人英博博士接受采访时透露,艾博生物联合军事科学院军事医学研究院、云南沃森生物共同研制的新型冠状病毒mRNA疫苗(ARCoV)已进入II期临床尾声,一切进展顺利。

将在5月与泰格医药紧密合作开展海外III期临床试验。从2021年第三季度开始全年有1.2亿支产能,对外出口多人份产能可达到数亿剂,实现中国mRNA疫苗“零”的突破。

与此同时,艾博生物上周也对外宣布完成共计6亿元人民币的B轮融资,本轮投资由人保资本股权、国投创业、云锋基金共同领投,高瓴创投、泰福资本、聚明创投、济峰资本、弘晖资本等机构跟投。

投资将加速新冠疫苗研发速度和用于产业基地建设。英博称,下一轮融资计划已在进行中,亦不排除未来公司上市的可能性。

实现中国mRNA疫苗“零”突破

mRNA,即Messenger RNA(信使核糖核酸),是把遗传信息从DNA传递到蛋白质的信使,为人体细胞提供指令,产生靶标蛋白(即抗原),从而激活人体免疫反应,抵抗相应的病毒。

截至目前,全球共有两款mRNA疫苗获批,分别为德国BioNTech公司与辉瑞合作研发的BNT162b2与美国Moderna公司研发的mRNA-1273,二者在临床试验中展现出的保护率均超过90%,是目前国际上保护率数据最高的新冠疫苗。

但两者储运温度条件相对苛刻,分别需要摄氏零下-70度(BNT162b2)和-20度(mRNA-1273)。

艾博生物是中国最早从事mRNA药物研发的公司之一,2019年初创建于苏州工业园区,2020年联合军事科学院军事医学研究院、云南沃森生物成功研发了首个中国进入临床的新冠ARCoV疫苗。

“不管是动物体内实验还是临床实验,从我们拿到的结果来看,国产ARCoV疫苗产品与海外两个mRNA疫苗完全可比。”英博表示。

SARS-CoV-2疫苗能在小鼠和非人灵长类动物中引起保护性免疫反应

据悉,ARCoV前两期临床数据较理想,预期最快在2021年4月底拿到III期海外临床批文, 5月份正式开启海外多中心临床试验。

对III期临床选择的具体国家,或首选南美洲,“会考虑当地疫情的情况,缺乏研发能力和疫苗供给的国家优先考量,这样能有效帮助当地控制疫情。”

对比辉瑞疫苗,ARCoV的差异在于可在2-8摄氏度环境下保存。在医学期刊《细胞》(Cell)上公布的动物试验中,为了评估ARCoV的热稳定性,军事医学科学院秦成峰教授团队将疫苗最长在常温中储存7天,然后将它注射到小鼠体内仍然有效。这使得ARCoV可以大大降低冷链运输的挑战。

和其他类别的疫苗相比,mRNA疫苗最大的优势在于生产环节及研发周期短,工艺相对简单,可以快速推进生产。

据2020年12月消息,ARCoV工业化方面由沃森生物主要负责,沃森生物用于生产mRNA新冠疫苗的生产车间在云南玉溪开工,投资2.8亿元,预计产能每年1.2亿。

针对病毒变异,或与现有疫苗形成互补

从现有情况来看,由于不断变异,全世界各国与新冠疫情的斗争是长期持续的。由于数据不足,目前对于打两种疫苗“交叉接种”,国际舆论尚有争议。

但英博认为,mRNA疫苗除了单独使用有很好的预防效果,还可以跟现有疫苗形成一个良好的互补。比如,为灭活病毒疫苗增加细胞免疫;给腺病毒载体的疫苗进行第二针的接种。

“mRNA疫苗对变异毒株的研发和生产的速度是最快的。交叉使用是1+1>2的功效。这样可以快速有效的抵抗变异的新冠疫情。”

近日在成都举办的第二届疫苗与健康大会上,中国疾控中心主任高福院士也表示,针对现有疫苗保护率问题,可通过优化接种程序(增加剂次,改变剂量,改变间隔等);考虑不同技术路线疫苗的混合接种取长补短来解决。

与传统的生物技术相比,mRNA在疫苗中的应用优势是灵活和快速,传统的疫苗研发技术往往需要较长时间才能生产和纯化蛋白质并生产疫苗,而向遗传基因插入人工合成的mRNA来改变其靶标,可使其产生特定的抗体。因此,mRNA技术为艾滋病及癌症防治方面也带来无限遐想。

目前艾博生物已建立丰富的产品管线,治疗领域涵盖肿瘤免疫、传染病预防、各种由于蛋白表达或功能缺失引起的疾病、通用型及个性化肿瘤疫苗等。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1947381, encodeId=80aa194e3818a, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15565, encryptionId=88d81556543, topicName=RNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sat Oct 09 15:08:05 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065647, encodeId=2119106564e87, content=<a href='/topic/show?id=43c112234fc' target=_blank style='color:#2F92EE;'>#mRNA疫苗#</a>进展并不顺利呀!因为国外愿意打疫苗的,都已经打了,余下不愿意接种的,也不想接种。因此,招募病人会变得越来越困难!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12234, encryptionId=43c112234fc, topicName=mRNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Oct 31 23:41:23 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916421, encodeId=652419164211e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Jan 20 23:08:05 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653176, encodeId=02be16531e637, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Fri Jan 07 13:08:05 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957825, encodeId=706195e82510, content=<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51728, encryptionId=974e51e2810, topicName=心血管)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200817/5fe8f33f21704f9fa146467225104f3d/79e15ccb924b4443a8a1272e4cd4f960.jpg, createdBy=c7971693678, createdName=1de64367m34(暂无匿称), createdTime=Sat Apr 17 14:25:18 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957824, encodeId=235395e82450, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200817/5fe8f33f21704f9fa146467225104f3d/79e15ccb924b4443a8a1272e4cd4f960.jpg, createdBy=c7971693678, createdName=1de64367m34(暂无匿称), createdTime=Sat Apr 17 14:25:10 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524941, encodeId=9fc315249411a, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Fri Apr 16 12:08:05 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594878, encodeId=371f15948e849, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Apr 16 12:08:05 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029382, encodeId=220f102938203, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Apr 15 00:08:05 CST 2021, time=2021-04-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1947381, encodeId=80aa194e3818a, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15565, encryptionId=88d81556543, topicName=RNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sat Oct 09 15:08:05 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065647, encodeId=2119106564e87, content=<a href='/topic/show?id=43c112234fc' target=_blank style='color:#2F92EE;'>#mRNA疫苗#</a>进展并不顺利呀!因为国外愿意打疫苗的,都已经打了,余下不愿意接种的,也不想接种。因此,招募病人会变得越来越困难!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12234, encryptionId=43c112234fc, topicName=mRNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Oct 31 23:41:23 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916421, encodeId=652419164211e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Jan 20 23:08:05 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653176, encodeId=02be16531e637, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Fri Jan 07 13:08:05 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957825, encodeId=706195e82510, content=<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51728, encryptionId=974e51e2810, topicName=心血管)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200817/5fe8f33f21704f9fa146467225104f3d/79e15ccb924b4443a8a1272e4cd4f960.jpg, createdBy=c7971693678, createdName=1de64367m34(暂无匿称), createdTime=Sat Apr 17 14:25:18 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957824, encodeId=235395e82450, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200817/5fe8f33f21704f9fa146467225104f3d/79e15ccb924b4443a8a1272e4cd4f960.jpg, createdBy=c7971693678, createdName=1de64367m34(暂无匿称), createdTime=Sat Apr 17 14:25:10 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524941, encodeId=9fc315249411a, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Fri Apr 16 12:08:05 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594878, encodeId=371f15948e849, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Apr 16 12:08:05 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029382, encodeId=220f102938203, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Apr 15 00:08:05 CST 2021, time=2021-04-15, status=1, ipAttribution=)]
    2021-10-31 病毒猎手

    #mRNA疫苗#进展并不顺利呀!因为国外愿意打疫苗的,都已经打了,余下不愿意接种的,也不想接种。因此,招募病人会变得越来越困难!!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1947381, encodeId=80aa194e3818a, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15565, encryptionId=88d81556543, topicName=RNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sat Oct 09 15:08:05 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065647, encodeId=2119106564e87, content=<a href='/topic/show?id=43c112234fc' target=_blank style='color:#2F92EE;'>#mRNA疫苗#</a>进展并不顺利呀!因为国外愿意打疫苗的,都已经打了,余下不愿意接种的,也不想接种。因此,招募病人会变得越来越困难!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12234, encryptionId=43c112234fc, topicName=mRNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Oct 31 23:41:23 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916421, encodeId=652419164211e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Jan 20 23:08:05 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653176, encodeId=02be16531e637, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Fri Jan 07 13:08:05 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957825, encodeId=706195e82510, content=<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51728, encryptionId=974e51e2810, topicName=心血管)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200817/5fe8f33f21704f9fa146467225104f3d/79e15ccb924b4443a8a1272e4cd4f960.jpg, createdBy=c7971693678, createdName=1de64367m34(暂无匿称), createdTime=Sat Apr 17 14:25:18 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957824, encodeId=235395e82450, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200817/5fe8f33f21704f9fa146467225104f3d/79e15ccb924b4443a8a1272e4cd4f960.jpg, createdBy=c7971693678, createdName=1de64367m34(暂无匿称), createdTime=Sat Apr 17 14:25:10 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524941, encodeId=9fc315249411a, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Fri Apr 16 12:08:05 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594878, encodeId=371f15948e849, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Apr 16 12:08:05 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029382, encodeId=220f102938203, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Apr 15 00:08:05 CST 2021, time=2021-04-15, status=1, ipAttribution=)]
    2022-01-20 juliusluan78
  4. [GetPortalCommentsPageByObjectIdResponse(id=1947381, encodeId=80aa194e3818a, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15565, encryptionId=88d81556543, topicName=RNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sat Oct 09 15:08:05 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065647, encodeId=2119106564e87, content=<a href='/topic/show?id=43c112234fc' target=_blank style='color:#2F92EE;'>#mRNA疫苗#</a>进展并不顺利呀!因为国外愿意打疫苗的,都已经打了,余下不愿意接种的,也不想接种。因此,招募病人会变得越来越困难!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12234, encryptionId=43c112234fc, topicName=mRNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Oct 31 23:41:23 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916421, encodeId=652419164211e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Jan 20 23:08:05 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653176, encodeId=02be16531e637, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Fri Jan 07 13:08:05 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957825, encodeId=706195e82510, content=<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51728, encryptionId=974e51e2810, topicName=心血管)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200817/5fe8f33f21704f9fa146467225104f3d/79e15ccb924b4443a8a1272e4cd4f960.jpg, createdBy=c7971693678, createdName=1de64367m34(暂无匿称), createdTime=Sat Apr 17 14:25:18 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957824, encodeId=235395e82450, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200817/5fe8f33f21704f9fa146467225104f3d/79e15ccb924b4443a8a1272e4cd4f960.jpg, createdBy=c7971693678, createdName=1de64367m34(暂无匿称), createdTime=Sat Apr 17 14:25:10 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524941, encodeId=9fc315249411a, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Fri Apr 16 12:08:05 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594878, encodeId=371f15948e849, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Apr 16 12:08:05 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029382, encodeId=220f102938203, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Apr 15 00:08:05 CST 2021, time=2021-04-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1947381, encodeId=80aa194e3818a, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15565, encryptionId=88d81556543, topicName=RNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sat Oct 09 15:08:05 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065647, encodeId=2119106564e87, content=<a href='/topic/show?id=43c112234fc' target=_blank style='color:#2F92EE;'>#mRNA疫苗#</a>进展并不顺利呀!因为国外愿意打疫苗的,都已经打了,余下不愿意接种的,也不想接种。因此,招募病人会变得越来越困难!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12234, encryptionId=43c112234fc, topicName=mRNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Oct 31 23:41:23 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916421, encodeId=652419164211e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Jan 20 23:08:05 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653176, encodeId=02be16531e637, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Fri Jan 07 13:08:05 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957825, encodeId=706195e82510, content=<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51728, encryptionId=974e51e2810, topicName=心血管)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200817/5fe8f33f21704f9fa146467225104f3d/79e15ccb924b4443a8a1272e4cd4f960.jpg, createdBy=c7971693678, createdName=1de64367m34(暂无匿称), createdTime=Sat Apr 17 14:25:18 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957824, encodeId=235395e82450, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200817/5fe8f33f21704f9fa146467225104f3d/79e15ccb924b4443a8a1272e4cd4f960.jpg, createdBy=c7971693678, createdName=1de64367m34(暂无匿称), createdTime=Sat Apr 17 14:25:10 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524941, encodeId=9fc315249411a, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Fri Apr 16 12:08:05 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594878, encodeId=371f15948e849, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Apr 16 12:08:05 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029382, encodeId=220f102938203, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Apr 15 00:08:05 CST 2021, time=2021-04-15, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1947381, encodeId=80aa194e3818a, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15565, encryptionId=88d81556543, topicName=RNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sat Oct 09 15:08:05 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065647, encodeId=2119106564e87, content=<a href='/topic/show?id=43c112234fc' target=_blank style='color:#2F92EE;'>#mRNA疫苗#</a>进展并不顺利呀!因为国外愿意打疫苗的,都已经打了,余下不愿意接种的,也不想接种。因此,招募病人会变得越来越困难!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12234, encryptionId=43c112234fc, topicName=mRNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Oct 31 23:41:23 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916421, encodeId=652419164211e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Jan 20 23:08:05 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653176, encodeId=02be16531e637, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Fri Jan 07 13:08:05 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957825, encodeId=706195e82510, content=<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51728, encryptionId=974e51e2810, topicName=心血管)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200817/5fe8f33f21704f9fa146467225104f3d/79e15ccb924b4443a8a1272e4cd4f960.jpg, createdBy=c7971693678, createdName=1de64367m34(暂无匿称), createdTime=Sat Apr 17 14:25:18 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957824, encodeId=235395e82450, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200817/5fe8f33f21704f9fa146467225104f3d/79e15ccb924b4443a8a1272e4cd4f960.jpg, createdBy=c7971693678, createdName=1de64367m34(暂无匿称), createdTime=Sat Apr 17 14:25:10 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524941, encodeId=9fc315249411a, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Fri Apr 16 12:08:05 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594878, encodeId=371f15948e849, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Apr 16 12:08:05 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029382, encodeId=220f102938203, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Apr 15 00:08:05 CST 2021, time=2021-04-15, status=1, ipAttribution=)]
    2021-04-17 1de64367m34(暂无匿称)

    学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1947381, encodeId=80aa194e3818a, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15565, encryptionId=88d81556543, topicName=RNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sat Oct 09 15:08:05 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065647, encodeId=2119106564e87, content=<a href='/topic/show?id=43c112234fc' target=_blank style='color:#2F92EE;'>#mRNA疫苗#</a>进展并不顺利呀!因为国外愿意打疫苗的,都已经打了,余下不愿意接种的,也不想接种。因此,招募病人会变得越来越困难!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12234, encryptionId=43c112234fc, topicName=mRNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Oct 31 23:41:23 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916421, encodeId=652419164211e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Jan 20 23:08:05 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653176, encodeId=02be16531e637, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Fri Jan 07 13:08:05 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957825, encodeId=706195e82510, content=<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51728, encryptionId=974e51e2810, topicName=心血管)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200817/5fe8f33f21704f9fa146467225104f3d/79e15ccb924b4443a8a1272e4cd4f960.jpg, createdBy=c7971693678, createdName=1de64367m34(暂无匿称), createdTime=Sat Apr 17 14:25:18 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957824, encodeId=235395e82450, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200817/5fe8f33f21704f9fa146467225104f3d/79e15ccb924b4443a8a1272e4cd4f960.jpg, createdBy=c7971693678, createdName=1de64367m34(暂无匿称), createdTime=Sat Apr 17 14:25:10 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524941, encodeId=9fc315249411a, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Fri Apr 16 12:08:05 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594878, encodeId=371f15948e849, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Apr 16 12:08:05 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029382, encodeId=220f102938203, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Apr 15 00:08:05 CST 2021, time=2021-04-15, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1947381, encodeId=80aa194e3818a, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15565, encryptionId=88d81556543, topicName=RNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sat Oct 09 15:08:05 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065647, encodeId=2119106564e87, content=<a href='/topic/show?id=43c112234fc' target=_blank style='color:#2F92EE;'>#mRNA疫苗#</a>进展并不顺利呀!因为国外愿意打疫苗的,都已经打了,余下不愿意接种的,也不想接种。因此,招募病人会变得越来越困难!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12234, encryptionId=43c112234fc, topicName=mRNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Oct 31 23:41:23 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916421, encodeId=652419164211e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Jan 20 23:08:05 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653176, encodeId=02be16531e637, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Fri Jan 07 13:08:05 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957825, encodeId=706195e82510, content=<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51728, encryptionId=974e51e2810, topicName=心血管)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200817/5fe8f33f21704f9fa146467225104f3d/79e15ccb924b4443a8a1272e4cd4f960.jpg, createdBy=c7971693678, createdName=1de64367m34(暂无匿称), createdTime=Sat Apr 17 14:25:18 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957824, encodeId=235395e82450, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200817/5fe8f33f21704f9fa146467225104f3d/79e15ccb924b4443a8a1272e4cd4f960.jpg, createdBy=c7971693678, createdName=1de64367m34(暂无匿称), createdTime=Sat Apr 17 14:25:10 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524941, encodeId=9fc315249411a, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Fri Apr 16 12:08:05 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594878, encodeId=371f15948e849, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Apr 16 12:08:05 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029382, encodeId=220f102938203, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Apr 15 00:08:05 CST 2021, time=2021-04-15, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1947381, encodeId=80aa194e3818a, content=<a href='/topic/show?id=88d81556543' target=_blank style='color:#2F92EE;'>#RNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15565, encryptionId=88d81556543, topicName=RNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sat Oct 09 15:08:05 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065647, encodeId=2119106564e87, content=<a href='/topic/show?id=43c112234fc' target=_blank style='color:#2F92EE;'>#mRNA疫苗#</a>进展并不顺利呀!因为国外愿意打疫苗的,都已经打了,余下不愿意接种的,也不想接种。因此,招募病人会变得越来越困难!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12234, encryptionId=43c112234fc, topicName=mRNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Oct 31 23:41:23 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916421, encodeId=652419164211e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Jan 20 23:08:05 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653176, encodeId=02be16531e637, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Fri Jan 07 13:08:05 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957825, encodeId=706195e82510, content=<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51728, encryptionId=974e51e2810, topicName=心血管)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200817/5fe8f33f21704f9fa146467225104f3d/79e15ccb924b4443a8a1272e4cd4f960.jpg, createdBy=c7971693678, createdName=1de64367m34(暂无匿称), createdTime=Sat Apr 17 14:25:18 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957824, encodeId=235395e82450, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200817/5fe8f33f21704f9fa146467225104f3d/79e15ccb924b4443a8a1272e4cd4f960.jpg, createdBy=c7971693678, createdName=1de64367m34(暂无匿称), createdTime=Sat Apr 17 14:25:10 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524941, encodeId=9fc315249411a, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Fri Apr 16 12:08:05 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594878, encodeId=371f15948e849, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Apr 16 12:08:05 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029382, encodeId=220f102938203, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Apr 15 00:08:05 CST 2021, time=2021-04-15, status=1, ipAttribution=)]
    2021-04-15 公卫新人

    新冠肺炎,疫情何时才能消失

    0